|11. Switch to a different TNFi biologic monotherapy over switching to a different TNFi biologic and MTX combination therapy (PICO 30)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider switching to a TNFi biologic and MTX combination therapy if the current TNFi biologic is infliximab.| |
|12. Switch to an IL-17i biologic monotherapy over switching to an IL-17i biologic and MTX combination therapy (PICO 32)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-17i biologic and MTX combination therapy in patients with concomitant uveitis, as uveitis may respond to MTX therapy.| |
|13. Switch to an IL-12/23i biologic monotherapy over switching to an IL-12/23i biologic and MTX combination therapy (PICO 31)|Very low|
|---|---|